MetaCap

enGene Therapeutics (ENGN) vs Molecular Partners (MOLN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Molecular Partners (MOLN) has outperformed enGene Therapeutics (ENGN) over the past year, losing 37.5% versus a loss of 75.0%. enGene Therapeutics is the larger company by market cap ($116.6 million vs $96.8 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENGN-75.00%MOLN-37.50%
+83%-2%-87%
Nov 21, 20251 yearNov 20, 2026
ENGN-82.35%MOLN-90.53%
+202%+49%-104%
Jan 31, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENGN versus MOLN key metrics
MetricENGNMOLN
Share price$1.74$2.53
Market cap$116.61M$96.80M
1-day change-1.14%-5.25%
YTD return-80.73%-42.07%
1-year return-75.00%-37.50%
5-year return—-77.87%
EPS (TTM)$-2.07$-1.68
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-117.30M—
52-week high$12.25$5.36
52-week low$1.40$2.52
Distance from 52-week high-85.80%-52.89%
Analyst consensusbuystrong_buy
Avg. price target upside+146.55%+295.64%
Average volume1.12M1.63K
Shares outstanding67.02M38.34M
Employees81134
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MOLN has outperformed ENGN by 37.5 percentage points over the past year.

About enGene Therapeutics

ENGN stock →

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees

About Molecular Partners

MOLN stock →

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees

ENGN vs MOLN FAQ

Which is bigger, enGene Therapeutics or Molecular Partners?

enGene Therapeutics (ENGN) is larger, with a market capitalization of $116.61M compared with $96.80M for Molecular Partners (MOLN).

Which stock has performed better over the past year, ENGN or MOLN?

MOLN returned -37.50% over the past 12 months, compared with -75.00% for ENGN (price return, excluding dividends). Past performance does not predict future results.

Are enGene Therapeutics and Molecular Partners in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons